Key result
Fluvastatin cuts CMV viral particle concentration by ~97% in human endothelial cells.
Why the study?
Does fluvastatin inhibit CMV replication in human umbilical vein endothelial cells?
Does fluvastatin inhibit CMV replication in human umbilical vein endothelial cells?
Absolute Event Rate: 0.34% vs 10.5%
p-value: p=<0.001
Fluvastatin inhibits CMV replication in human endothelial cells, suggesting a potential mechanism for the anti-inflammatory and anti-atherosclerotic effects of statins.
BACKGROUND: Statins exert anti-inflammatory effects independently of cholesterol-lowering properties. Cytomegalovirus (CMV) infection appears to be implicated in the pathophysiology of atherosclerosis by inducing inflammatory modifications in endothelial cells, especially in immunosuppressed patients. We investigated whether the activity of statins can inhibit replication of CMV in human endothelial cells. METHODS AND RESULTS: Human umbilical vein endothelial cells (HUVECs) were infected with CMV and coincubated with fluvastatin at 0.1 and 0.2 micromol/L. Fluvastatin inhibited (P<0.001) CMV antigen expression, and this effect was dose related (P<0.001). Quantitative polymerase chain reaction showed that CMV DNA concentration was consistently lower in supernatants from fluvastatin-treated cells than in infected controls, and viral particle concentration was up to 30 times lower in 0.2 micromol/L fluvastatin-treated cells than in infected controls (10.5+/-0.9 versus 0.34+/-0.03 per 10(3) pfu/mL, P<0.001). Addition of mevalonate to treated cultures almost completely abolished fluvastatin inhibition of viral growth. Electrophoretic mobility shift assay showed that fluvastatin reduced nuclear factor-kappaB binding activity in CMV-infected cells. CONCLUSIONS: HMG-CoA inhibition by fluvastatin restrains CMV replication in HUVECs by inhibiting viral antigen expression, DNA synthesis, and viral particle production, conceivably by involving a reduction of nuclear factor-kappaB binding activity.
No takes yet. Share an insight, caveat, or question.
Potena et al. (2004) studied Cytomegalovirus (CMV) infection. Fluvastatin vs. Infected controls was evaluated on Viral particle concentration (per 10^3 pfu/mL) (p=<0.001). Fluvastatin at 0.2 micromol/L significantly reduced viral particle concentration in CMV-infected human endothelial cells compared to infected controls (0.34 vs 10.5 per 10^3 pfu/mL, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: